Annals of Oncology 13:1628-1635, 2002
© 2002 European Society for Medical Oncology
Original Paper |
Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease
1 Klinik I für Innere Medizin, Universität zu Köln, Köln; 2 II. Medizinische Klinik, Carl-Thiem-Klinikum, Cottbus; 3 Abteilung für Hämatologie, Onkologie und Tumorimmunologie, Max-Delbrück-Centrum für Molekulare Medizin, Campus Buch, Humboldt-Universität Berlin, Berlin-Buch; 4 Klinik für Hämatologie und Onkologie, Medizinische Klinik III, Klinikum Hannover–Siloah, Hannover; 5 Abteilung Onkologie und Hämatologie, Medizinische Klinik, Universitätskrankenhaus Eppendorf, Hamburg, Germany
Received 29 October 2001; revised 11 February 2002, accepted 11 March 2002
Background:
An important variable affecting outcome in relapsed and refractory Hodgkin’s disease (HD) is the potential of conventional salvage chemotherapy to reduce tumor volume before high-dose chemotherapy (HDCT) and autologous stem cell transplantation. Currently, the optimal salvage chemotherapy regimen for these patients is unclear. Since dexamethasone/cisplatin/cytarabine (DHAP) given at 3–4 week intervals has been shown to be very effective in patients with relapsed aggressive non-Hodgkin’s lymphoma, we evaluated this regimen given at a median of 16-day intervals in patients with relapsed and refractory HD.
Patients and methods:
Patients with relapsed or refractory HD were treated with two cycles of DHAP [dexamethasone 40 mg intravenously (i.v.) day 1–4, cisplatin 100 mg/m2 i.v. as 24-h continuous infusion day 1, and cytarabine 2 g/m2 i.v. 12q day 2]. Granulocyte colony-stimulating factor (G-CSF) was given at a dose of 5 µg/kg from day 4 until day 13. Patients with partial remission (PR) or complete remission (CR) after two cycles of DHAP received sequential HDCT.
Results:
The median age of the 102 patients included was 34 years (range 21–64 years). Forty-two percent of the patients had late relapse, 29% early relapse, 12% multiple relapse and 16% primary progressive/refractory disease. The response rate (RR) after two cycles of DHAP was 89% (21% CR, 68% PR). The RRs for patients with late, early, multiple and progressive HD were 91%, 93%, 92% and 65%, respectively. Using the chi-square test for independence, remission status (relapsed HD versus progressive HD) and stage at relapse (stage I/II versus stage III/IV) were significant factors for response to DHAP. WHO grade 4 leukocytopenia and thrombocytopenia were the main toxic- ities occurring in 43% (mean duration 1.1 days, range 0–6) and 48% (mean duration 1.4 days, range 0–11) of all courses, respectively. Neither severe infections nor treatment-related deaths occurred. Peripheral blood stem cells (PBSCs) were collected after the first cycle DHAP in eight patients. The hematopoietic progenitors showed a very rapid increase from day 10 with a synchronous and impressive peak on day 12. A mean of 6.1 x 106/kg CD34+ cells were collected per apheresis. As originally recommended in the protocol, PBSCs were routinely collected during sequential HDCT in the remaining patients.
Conclusions:
A brief tumor-reducing program with two cycles of DHAP given in short intervals supported by G-CSF is effective and well-tolerated in patients with relapsed and refractory HD. This regimen can be used to mobilize stem cells and select those patients with chemosensitive relapse who should subsequently be treated with HDCT.
Key words: Hodgkin’s disease, relapse, salvage chemotherapy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Fernandez de Larrea, C. Martinez, A. Gaya, A. Lopez-Guillermo, M. Rovira, F. Fernandez-Aviles, M. Lozano, F. Bosch, J. Esteve, B. Nomdedeu, et al. Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation Ann. Onc., November 4, 2009; (2009) mdp487v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Brusamolino, A. Bacigalupo, G. Barosi, G. Biti, P. G. Gobbi, A. Levis, M. Marchetti, A. Santoro, P. L. Zinzani, and S. Tura Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up Haematologica, April 1, 2009; 94(4): 550 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Byrne and J. P. Gockerman Salvage Therapy in Hodgkin's Lymphoma Oncologist, February 1, 2007; 12(2): 156 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Greenberg, P. A. Boria, A. Borgatti-Jeffreys, R. E. Raskin, and M. D. Lucroy Phase II Clinical Trial of Combination Chemotherapy With Dexamethasone for Lymphoma in Dogs J. Am. Anim. Hosp. Assoc., January 1, 2007; 43(1): 27 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Brusamolino and A. M. Carella Treatment of refractory and relapsed Hodgkin's lymphoma: facts and perspectives Haematologica, January 1, 2007; 92(1): 6 - 10. [Full Text] [PDF]
|
|
|
|
|
|
A. Santoro, M. Magagnoli, M. Spina, G. Pinotti, L. Siracusano, M. Michieli, A. Nozza, B. Sarina, E. Morenghi, L. Castagna, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma Haematologica, January 1, 2007; 92(1): 35 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Schellong, W. Dorffel, A. Claviez, D. Korholz, G. Mann, H.-G. Scheel-Walter, J. P.M. Bokkerink, M. Riepenhausen, H. Luders, R. Potter, et al. Salvage Therapy of Progressive and Recurrent Hodgkin's Disease: Results From a Multicenter Study of the Pediatric DAL/GPOH-HD Study Group J. Clin. Oncol., September 1, 2005; 23(25): 6181 - 6189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Josting, M. Sieniawski, J.-P. Glossmann, O. Staak, L. Nogova, N. Peters, M. Mapara, B. Dorken, Y. Ko, B. Metzner, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study Ann. Onc., August 1, 2005; 16(8): 1359 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Re, R. K. Thomas, K. Behringer, and V. Diehl From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential Blood, June 15, 2005; 105(12): 4553 - 4560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Josting, C. Rudolph, M. Mapara, J.-P. Glossmann, M. Sienawski, M. Sieber, H. H. Kirchner, B. Dorken, D. K. Hossfeld, J. Kisro, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG) Ann. Onc., January 1, 2005; 16(1): 116 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Bartlett Therapies for Relapsed Hodgkin Lymphoma: Transplant and Non-Transplant Approaches Including Immunotherapy Hematology, January 1, 2005; 2005(1): 245 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. E. Lieskovsky, S. S. Donaldson, M. A. Torres, R. M. Wong, M. D. Amylon, M. P. Link, and R. Agarwal High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation for Recurrent or Refractory Pediatric Hodgkin's Disease: Results and Prognostic Indices J. Clin. Oncol., November 15, 2004; 22(22): 4532 - 4540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Baetz, A. Belch, S. Couban, K. Imrie, J. Yau, R. Myers, K. Ding, N. Paul, L. Shepherd, J. Iglesias, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group Ann. Onc., December 1, 2003; 14(12): 1762 - 1767. [Abstract] [Full Text] [PDF]
|
|